Patients on taranabant lost an average of 14.5 pounds (6.6 kilograms) compared with 5.7 lbs (2.6 kg) for those on a placebo after 52 weeks -- a difference deemed statistically significant, Merck said in a statement.
NEW YORK (Reuters) - Merck & Co said on Monday that patients on its experimental obesity drug lost more than twice as much weight as those on a placebo in a late-stage clinical study.
Patients on taranabant lost an average of 14.5 pounds (6.6 kilograms) compared with 5.7 lbs (2.6 kg) for those on a placebo after 52 weeks -- a difference deemed statistically significant, Merck said in a statement.
The findings were presented at the American College of Cardiology conference in Chicago.
(Reporting by Lewis Krauskopf, editing by Gerald E. McCormick)
!ADVERTISEMENT!
